A Phase II Trial of Sequential SGN-35 Therapy With Adriamycin, Vinblastine, and Dacarbazine (S-AVD) for Older Patients With Untreated Hodgkin Lymphoma

Trial Profile

A Phase II Trial of Sequential SGN-35 Therapy With Adriamycin, Vinblastine, and Dacarbazine (S-AVD) for Older Patients With Untreated Hodgkin Lymphoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Feb 2018

At a glance

  • Drugs Brentuximab vedotin (Primary) ; Dacarbazine; Doxorubicin; Vinblastine
  • Indications Hodgkin's disease
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 01 Feb 2018 Planned End Date changed from 1 May 2018 to 1 May 2019.
    • 01 Feb 2018 Planned primary completion date changed from 1 May 2017 to 1 May 2018.
    • 12 Dec 2017 Results assessing efficacy and tolerability of sequential brentuximab vedotin then doxorubicin + vinblastine + dacarbazine following by consolidation brentuximab vedotin in the event of complete response, in patients with untreated stage II-IV Hodgkin's disease aged 60 years and older, were presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top